Anti-CD1a Antibodies for Targeted Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies and treatments fail to effectively address the challenges of inflammatory skin and mucosal diseases, associated systemic disorders, and CD1a-expressing malignancies by targeting the CD1a antigen presentation pathway.
Innovation Solution
Development of anti-CD1a antibodies that specifically bind to CD1a, inducing cell death and blocking ligand binding, thereby modulating the immune response and treating or preventing inflammatory diseases and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for inflammatory skin and mucosal diseases, then general anti-inflammatory effects are achieved, but effective targeting of the CD1a antigen presentation pathway is not achieved
Solution Approach 1:
The patent introduces anti-CD1a antibodies as intermediary molecules that specifically bind to CD1a on antigen-presenting cells. These antibodies mediate the therapeutic effect by blocking the CD1a antigen presentation pathway, thereby resolving the contradiction between achieving reliable treatment and enabling specific pathway targeting.
2Object-affected harmful factors
If broad-spectrum immunosuppressants are used, then general inflammation is reduced, but CD1a-specific immune responses are not effectively modulated
Solution Approach 1:
The patent applies local quality by designing antibodies with specific affinity for CD1a molecules. This enables selective modulation of CD1a-mediated immune responses in skin and mucosal tissues while preserving other immune functions, thereby reducing inflammation with high specificity rather than broad immunosuppression.
Solution Approach 2:
The patent utilizes parameter changes by modifying the binding characteristics of anti-CD1a antibodies through engineered variable regions. This allows optimization of antibody affinity and specificity for CD1a, enabling precise control over the magnitude and duration of immune modulation to achieve targeted inflammation reduction.
3Ease of operation
If conventional therapies are applied, then general disease symptoms are managed, but CD1a-expressing cell populations are not specifically targeted
Solution Approach 1:
The patent extracts the CD1a antigen presentation pathway as a specific therapeutic target from the complex immune system. By developing antibodies that selectively bind to CD1a, the invention isolates and targets this specific pathway without requiring complex multi-component therapies, maintaining operational simplicity while achieving high targeting accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD1a antibodies effectively target CD1a-expressing cells, reducing inflammation and disease severity, and providing therapeutic benefits for inflammatory skin and mucosal disorders, systemic disorders, and CD1a-expressing malignancies.
Implementation Method 1
an antibody or antigen binding fragment which is capable of binding to CD1a
Data Source
AI summary
The invention relates to an antibody or antigen binding fragment thereof which is capable of binding to CD1a. The antibody or antigen binding fragment thereof may be chimeric or humanised, and may be used to treat one or more inflammatory skin or mucosal disorder, or disease or one or more associated systemic disease or disorder, or one or more inflammatory drug reaction which manifests systemically, or a CD1a-expressing malignancy.